Payment overview · 2025
General Payments
$47.11
3 reported records · 2 companies
Healthcare provider profile · identity verified
Muhammad Wasiullah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALLEN PARK, MI · NPI 1295758415
Verified facts
What the public records show
CMS Open Payments records show Muhammad Wasiullah, MD received $47.11 in general payments during 2025 across 3 reported records.
Exact Sciences Corporation accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.68 | 58.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.43 | 41.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $47.11 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.68 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 527 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 301 | 54 |
| Alprazolam | Alprazolam | 286 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 242 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 241 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 233 | 22 |
| Lisinopril | Lisinopril | 219 | 39 |
| Meloxicam | Meloxicam | 212 | 30 |
| Omeprazole | Omeprazole | 187 | 34 |
| Metformin Hcl | Metformin Hcl | 183 | 31 |
| Gabapentin | Gabapentin | 178 | 23 |
| Furosemide | Furosemide | 143 | 29 |
| Losartan Potassium | Losartan Potassium | 139 | 29 |
| Trazodone Hcl | Trazodone Hcl | 139 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 116 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 15 |
| Simvastatin | Simvastatin | 99 | 19 |
| Famotidine | Famotidine | 97 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 18 |
| Trulicity | Dulaglutide | 83 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 13 |
| Pregabalin | Pregabalin | 74 | suppressed |
| Ibuprofen | Ibuprofen | 72 | 16 |
| Montelukast Sodium | Montelukast Sodium | 71 | 11 |
| Carvedilol | Carvedilol | 69 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 13 |
| Clonidine Hcl | Clonidine Hcl | 62 | 13 |
| Mirtazapine | Mirtazapine | 60 | suppressed |
| Eliquis | Apixaban | 58 | 11 |
| Ondansetron Odt | Ondansetron | 56 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Diazepam | Diazepam | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Lidocaine | Lidocaine | 43 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 11 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Prednisone | Prednisone | 38 | 26 |
| Atenolol | Atenolol | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | suppressed |
| Nystatin | Nystatin | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Aripiprazole Odt | Aripiprazole | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 17 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Klor-Con | Potassium Chloride | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47.11 · 3 records | Exact Sciences Corporation | Cologuard Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error